Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations

Diabetes Care

Volumn 31, Issue 2, 2008, Pages 204-209

  Rafiq, Meena ^a,b   Flanagan, Sarah E ^a   Patch, Ann Marie ^a   Shields, Beverley M ^a   Ellard, Sian ^a   Hattersley, Andrew T ^a   Batra, Chandar ^c   Bruining, Jan ^d   Carson, Dennis ^e   Codner, Ethel ^f   Cummings, Elizabeth ^g   Curran, Jacqueline ^h   Davis, Elizabeth ⁱ   Deiss, Dorothee ^j   Herr, Mathias ^j   Hussain, Khalid ^k   Legault, Laurent ^l   Malecki, Maciek ^m   Paskova, Magdalena ⁿ   Pearson, Ewan ^o   Rodda, Christine ^p   Rothenbuhler, Anya ^q   Sanchez, Juan ^r   Shield, Julian ^s   Stanca, Ràcealà Motoc ^t   Van Der Meulen, John ^u   more..

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Batra Hospital India   (India)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^f UNIVERSITY OF CHILE   (Chile)

^g IWK HEALTH CENTRE   (Canada)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^l MONTREAL CHILDREN S HOSPITAL   (Canada)

^m JAGIELLONIAN UNIVERSITY   (Poland)

ⁿ L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^o UNIVERSITY OF DUNDEE   (United Kingdom)

^p MONASH MEDICAL CENTRE   (Australia)

^q HÔPITAL SAINT VINCENT DE PAUL   (France)

^r RILEY HOSPITAL FOR CHILDREN   (United States)

^s BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^t Pediatrics Hospital of Sibiu   (Romania)

^u MCMASTER CHILDREN S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR 1; TOLBUTAMIDE;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE MUTATION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFANT; MALE; NAUSEA; PATHOGENESIS; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 38949177444     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-1785     Document Type: Article

References (20)

1. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838-1849, 2004
2. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B, Colclough K, Hattersley AT, Ashcroft FM, Ellard S: A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 15:1793-1800, 2006
3. Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, Robinson D, Shield JP, Temple K, Ellard S, Hattersley AT: Mutations in ATP-sensitive K channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56:1930-1937, 2007
4. Massa O, Iafusco D, D'Amato E, Gloyn AL, Hattersley AT, Pasquino B, Tonini G, Dammacco F, Zanette G, Meschi F, Porzio O, Bottazzo G, Crino A, Lorini R, Cerutti F, Vanelli M, Barbetti F: KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 25:22-27, 2005
5. Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, Hattersley AT, Czernichow P, Froguel P, Polak M: Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 53:2719-2722, 2004
6. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersly AT: Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life with the phenotype determined by genotype. Diabetologia 49:1190-1197, 2006
7. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, Edghill EL, Mackay DJG, Proks P, Shimomura K, Haberland H, Carson DJ, Shield JPH, Hattersley AT, Ashcroft FM: Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 81:375-382, 2007
8. Patch AM, Flanagan SE, Boustred C, Hattersley AT, Ellard S: Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes Obes Metab 9 (Suppl. 2):28-39, 2007
9. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 355:456-466, 2006
10. Vaxillaire M, Dechaume A, Busiah K, Cave H, Pereira S, Scharfmann R, de Nanclares GP, Castano L, Froguel P, Polak M: New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 56:1737-1741, 2007
11. Tucker SJ, Gribble FM, Zhao C, Trapp S, Ashcroft FM: Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Nature 387:179-183, 1997
12. Gloyn AL, Siddiqui J, Ellard S: Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 27:220-231, 2006
13. Ashcroft FM, Gribble FM: Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications 14:192-196, 2000
14. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Sovik O, Polak M, Hattersley AT: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467-477, 2006
15. Codner E, Flanagan SE, Ugarte F, García H, Vidal T, Ellard S, Hattersley AT: Sulfonylurea treatment in young children with neonatal diabetes: dealing with hyperglycemia, hypoglycemia, and sick days (Letter). Diabetes Care 30:e28-e29, 2007. DOI: 10.2337/dc06-2134
16. Masia R, De Leon DD, MacMullen C, McKnight H, Stanley CA, Nichols CG: A mutation in the TMD0-L0 region of sulfonylurea receptor-1 (L225P) causes permanent neonatal diabetes mellitus (PNDM). Diabetes 56:1357-1362, 2007
17. Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E, Ciljakova M, Hlava P, Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I: Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 92:1276-1282, 2007
18. Malecki MT, Skupien J, Klupa T, Wanic K, Mlynarski W, Gach A, Solecka I, Sieradzki J: Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating mutations: evidence for improvement in insulin sensitivity. Diabetes Care 30:147-149, 2007
19. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM: Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A 101:17539-17544, 2004
20. Trapp S, Proks P, Tucker SJ, Ashcroft FM: Molecular analysis of ATP-sensitive K channel gating and implications for channel inhibition by ATP. J Gen Physiol 112:333-349, 1998